The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
Open accessAbstract
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2–3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1–2% per year for the next 10 years. Testing should be done 2–3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4–6 months for 1 year and, if stable, every 6–12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationPrevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423 · cited 1×
“2% of 21,463 residents of Olmsted County, Minnesota, 50 years of age or older (2).”
BackgroundSelf-citationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Self-citationRajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A., & Katzmann, J. A. (2005) · Blood · doi:10.1182/blood-2005-03-1038 · Cited by 702
Self-citationPérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579
Self-citationDispenzieri, A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D., Benson, J., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2008) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 433
Self-citationSolitary plasmacytoma of bone and asymptomatic multiple myeloma
Dimopoulos, M. A., Moulopoulos, L. A., Maniatis, A., & Alexanian, R. (2000) · Blood · doi:10.1182/blood.v96.6.2037 · Cited by 397
Self-citationCesana, C., Klersy, C., Barbarano, L., Nosari, A., Crugnola, M., Pungolino, E. M., Gargantini, L., Granata, S., Valentini, M., & Morra, E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1625 · Cited by 259
Nowakowski, G. S., Witzig, T. E., Dingli, D., Tracz, M. J., Gertz, M. A., Lacy, M. Q., Lust, J. A., Dispenzieri, A., Greipp, P. R., Kyle, R. A., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1858 · Cited by 245
Self-citationClinically relevant end points and new drug approvals for myeloma
Anderson, K. C., Kyle, R. A., Rajkumar, S. V., Stewart, A. K., Weber, D., Richardson, P., & Myeloma, O. B. O. T. A. /. P. O. C. E. I. M. (2008) · Leukemia · doi:10.1038/sj.leu.2405016 · Cited by 225
Self-citationPrevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana
Landgren, O., Katzmann, J. A., Hsing, A. W., Pfeiffer, R. M., Kyle, R. A., Yeboah, E. D., Biritwum, R. B., Tettey, Y., Adjei, A. A., Larson, D. R., et al. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61089-6 · Cited by 194
Self-citationKyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., & Melton, L. J. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.859 · Cited by 194
Self-citationLandgren, O., Kristinsson, S. Y., Goldin, L. R., Caporaso, N. E., Blimark, C., Mellqvist, U.-H., Wahlin, A., Bjorkholm, M., & Turesson, I. (2009) · Blood · doi:10.1182/blood-2008-12-191676 · Cited by 167
Self-citationCohen, H. J., Crawford, J., Rao, M. K., Pieper, C. F., & Currie, M. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00080-1 · Cited by 162
Vachon, C. M., Kyle, R. A., Therneau, T. M., Foreman, B. J., Larson, D. R., Colby, C. L., Phelps, T. K., Dispenzieri, A. A., Kumar, S. K., Katzmann, J. A., et al. (2009) · Blood · doi:10.1182/blood-2008-12-192575 · Cited by 157
Self-citationMalignant transformation and life expectancy in monoclonal gammopathy of undetermined significance
Bladé, J., López‐Guillermo, A., Rozmán, C., Cervantes, F., Salgado, C., Aguilar, J., Corrons, J. V., & Montserrat, E. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08245.x · Cited by 151
Baldini, L., Guffanti, A., Cesana, B., Colombi, M., Chiorboli, O., Damilano, I., & Maiolo, A. T. (1996) · Blood · doi:10.1182/blood.v87.3.912.bloodjournal873912 · Cited by 123
Iwanaga, M., Tagawa, M., Tsukasaki, K., Kamihira, S., & Tomonaga, M. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61090-2 · Cited by 121
Rosiñol, L., Cibeira, M. T., Montoto, S., Rozman, M., Esteve, J., Filella, X., & Bladé, J. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.4.428 · Cited by 90
Singh, J., Dudley, A. W., & Kulig, K. A. (1990) · PubMed · Cited by 54
Kyle, R. A., Therneau, T. M., Melton, L. J., Dispenzieri, A. A., Larson, D. R., Benson, J. T., Katzmann, J. A., & Rajkumar, S. V. (2007) · Blood · doi:10.1182/blood.v110.11.246.246 · Cited by 10
Self-citation
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationWechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Multiple myeloma epidemiology and survival: A unique malignancy
Kazandjian, D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.004 · Cited by 765
Metadata
- Authors
- Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., San Miguel, J., Avet-Loiseau, H., Hajek, R., Chen, W. M., Anderson, K. C., Ludwig, H., Sonneveld, P., Pavlovsky, S., Palumbo, A., Richardson, P. G., Barlogie, B., Greipp, P., Vescio, R., Turesson, I., Westin, J., Boccadoro, M., & on behalf of the International Myeloma Working Group
- Venue
- Leukemia
- Published
- 2010-04-22
- Volume
- 24
- Issue
- 6
- Pages
- 1121-1127
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2170515647
- Cited by
- 888
- References
- 23
- FWCI
- 29.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.